

# Enzo Life Sciences (UK) Limited

Filleted Financial Statements  
for the Year Ended 31 July 2020

**Enzo Life Sciences (UK) Limited**  
**(Registration number: 02584159)**

**Contents**

Company Information	<u>1</u>
Balance Sheet	<u>2</u>
Notes to the Financial Statements	<u>3 to 6</u>

**Enzo Life Sciences (UK) Limited**  
**(Registration number: 02584159)**

**Company Information**

<b>Directors</b>	B Weiner D A Bench
<b>Registered office</b>	1 Colleton Crescent Exeter Devon EX2 4DG
<b>Auditors</b>	Thompson Jenner LLP Statutory Auditor 1 Colleton Crescent Exeter Devon EX2 4DG

**Enzo Life Sciences (UK) Limited**  
**(Registration number: 02584159)**

**Balance Sheet as at 31 July 2020**

	Note	2020 £	2019 £
<b>Current assets</b>			
Debtors	<u>4</u>	1,070,947	1,086,162
Cash at bank and in hand		<u>48,864</u>	<u>45,793</u>
		1,119,811	1,131,955
<b>Creditors:</b> Amounts falling due within one year	<u>5</u>	<u>(2,408,074)</u>	<u>(1,962,765)</u>
<b>Net liabilities</b>		<u>(1,288,263)</u>	<u>(830,810)</u>
<b>Capital and reserves</b>			
Called up share capital		616,691	616,691
Profit and loss account		<u>(1,904,954)</u>	<u>(1,447,501)</u>
<b>Total equity</b>		<u>(1,288,263)</u>	<u>(830,810)</u>

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime and the option not to file the Profit and Loss Account has been taken.

Approved and authorised by the Board on 22 March 2021 and signed on its behalf by:

.....

B Weiner  
Director

**Enzo Life Sciences (UK) Limited**  
**(Registration number: 02584159)**

**Notes to the Financial Statements for the Year Ended 31 July 2020**

**1 General information**

The company is a private company limited by share capital, incorporated in England & Wales.

The address of its registered office is:  
1 Colleton Crescent  
Exeter  
Devon  
EX2 4DG

**2 Accounting policies**

**Summary of significant accounting policies and key accounting estimates**

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

**Statement of compliance**

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A - 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.

**Basis of preparation**

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

The directors have considered the impact of COVID-19 and do not consider it to have a material impact on the balances included within the financial statements.

In addition, the Directors do not consider it to cast any significant doubt upon the company's ability to continue to trade as a going concern.

The directors have taken both reactive and proactive measures in order to mitigate any risks associated with COVID-19 including managing cash flow to ensure that debts can be paid when they fall due, managing staffing levels and monitoring key customer and supplier activity.

The directors have implemented a robust system of procedures and controls in order to deal with any associated risks.

**Going concern**

The company has made a loss during the year to 31 July 2020 and has net liabilities. The directors are confident that the company can trade profitably in the future.

The company has received confirmation of continued support from its parent company Axxora (UK) Ltd & the ultimate controlling party Enzo Biochem Inc. Therefore these accounts have been prepared on a going concern basis.

**Enzo Life Sciences (UK) Limited**  
**(Registration number: 02584159)**

**Notes to the Financial Statements for the Year Ended 31 July 2020**

**Audit report**

The Independent Auditors' Report was unqualified. The name of the Senior Statutory Auditor who signed the audit report on 31 March 2021 was Mr Jonathan Westley, who signed for and on behalf of Thompson Jenner LLP.

**Revenue recognition**

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company's activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:

The amount of revenue can be reliably measured;

it is probable that future economic benefits will flow to the entity;

and specific criteria have been met for each of the company's activities.

**Cash and cash equivalents**

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

**Trade debtors**

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

**Trade creditors**

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

**Share capital**

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

**Enzo Life Sciences (UK) Limited**  
**(Registration number: 02584159)**

**Notes to the Financial Statements for the Year Ended 31 July 2020**

**Defined contribution pension obligation**

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods. Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

**3 Staff numbers**

The average number of persons employed by the company (including directors) during the year, was 5 (2019 - 5).

**4 Debtors**

	<b>2020</b>	<b>2019</b>
	<b>£</b>	<b>£</b>
Trade debtors	159,624	282,630
Amounts owed by group undertakings and undertakings in which the company has a participating interest	909,495	803,482
Other debtors	1,828	50
	<u>1,070,947</u>	<u>1,086,162</u>
Total current trade and other debtors		

**5 Creditors**

	<b>2020</b>	<b>2019</b>
	<b>£</b>	<b>£</b>
<b>Due within one year</b>		
Trade creditors	727	9,832
Amounts owed to group undertakings and undertakings in which the company has a participating interest	2,325,622	1,870,871
Taxation and social security	31,851	38,509
Other creditors	1,205	1,460
Accrued expenses	48,669	42,093
	<u>2,408,074</u>	<u>1,962,765</u>

**6 Pension schemes**

The company operates a defined contribution pension scheme. The pension cost charge for the year represents contributions payable by the company to the scheme and amounted to £14,898 (2019 - £14,661). Contributions totalling £Nil (2019 - £Nil) were payable to the scheme at the end of the year.

**Enzo Life Sciences (UK) Limited**  
**(Registration number: 02584159)**

**Notes to the Financial Statements for the Year Ended 31 July 2020**

**7 Contingent assets**

The company has an unprovided deferred tax asset in respect of tax losses available to be set off against future taxable profits. This asset is valued at £382,943 (2019 - £295,684) and is calculated using a tax rate of 19% (2019 - 19%). Deferred tax balances are not discounted.

**8 Contingent liabilities**

Enzo Life Sciences (UK) Limited has set up an agreement with HM Revenue and Customs in respect of the deferred payment of duty after the balance sheet date. The amount guaranteed is £20,000.

**9 Related party transactions**

The company has taken advantage of the exemptions in FRS 102 Section 1A "Related Party Disclosures" from disclosing transactions with other members of the group and key management personnel.

**10 Parent and ultimate parent undertaking**

The company is controlled by Axxora (UK) Limited, the immediate parent company. The ultimate controlling party is Enzo Biochem Inc.

Enzo Biochem Inc. is a company incorporated in the state of New York in the United States of America and listed on the New York Stock Exchange.

Copies of the accounts are available from:

Investor and Public Relations

Anreder & Company

286 Madison Avenue

New York, NY10017

United States of America



Exeter

This document was delivered using electronic communications and authenticated in accordance with the  
Devon  
Exeter's rules relating to electronic form, authentication and manner of delivery under section 1072 of  
the Companies Act 2006.